Oxidative stress, defective proteostasis and immunometabolic complications in critically ill patients
European Journal of Clinical Investigation · 2024-09 · 54 (9)
DOI: 10.1111/eci.14229 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift European Journal of Clinical Investigation, online erschienen am 27.04.2024. Verfasst von Francesco Galli und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmaceutical Sciences, University of Perugia, Perugia, Italy. Hauptthemen laut MEDLINE: Critical Illness, Oxidative Stress, Proteostasis. Die Arbeit wurde bisher 20-mal zitiert (Crossref) und nennt 184 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Fondazione Cassa di Risparmio di Perugia, Italy (FG recipient), Fondazione Cassa di Risparmio di Perugia.
Abstract (Originalsprache)
Oxidative stress (OS) develops in critically ill patients as a metabolic consequence of the immunoinflammatory and degenerative processes of the tissues. These induce increased and/or dysregulated fluxes of reactive species enhancing their pro‐oxidant activity and toxicity. At the same time, OS sustains its own inflammatory and immunometabolic pathogenesis, leading to a pervasive and vitious cycle of events that contribute to defective immunity, organ dysfunction and poor prognosis. Protein damage is a key player of these OS effects; it generates increased levels of protein oxidation products and misfolded proteins in both the cellular and extracellular environment, and contributes to forms DAMPs and other proteinaceous material to be removed by endocytosis and proteostasis processes of different cell types, as endothelial cells, tissue resident monocytes‐macrophages and peripheral immune cells. An excess of OS and protein damage in critical illness can overwhelm such cellular processes ultimately interfering with systemic proteostasis, and consequently with innate immunity and cell death pathways of the tissues thus sustaining organ dysfunction mechanisms. Extracorporeal therapies based on biocompatible/bioactive membranes and new adsorption techniques may hold some potential in reducing the impact of OS on the defective proteostasis of patients with critical illness. These can help neutralizing reactive and toxic species, also removing solutes in a wide spectrum of molecular weights thus improving proteostasis and its immunometabolic corelates. Pharmacological therapy is also moving steps forward which could help to enhance the efficacy of extracorporeal treatments. This narrative review article explores the aspects behind the origin and pathogenic role of OS in intensive care and critically ill patients, with a focus on protein damage as a cause of impaired systemic proteostasis and immune dysfunction in critical illness.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmaceutical Sciences, University of Perugia, Perugia, Italy.
- Department of Medicine, International Renal Research Institute of Vicenza, University of Padova, San Bortolo Hospital Vicenza, Vicenza, Italy.
ORCID-Profile: Francesco Galli
Förderung
- Fondazione Cassa di Risparmio di Perugia, Italy (FG recipient)
- Fondazione Cassa di Risparmio di Perugia
Zitieren
APA
Galli, F., Bartolini, D., & Ronco, C. (2024). Oxidative stress, defective proteostasis and immunometabolic complications in critically ill patients. European Journal of Clinical Investigation, 54(9). https://doi.org/10.1111/eci.14229
Vancouver
Galli F, Bartolini D, Ronco C. Oxidative stress, defective proteostasis and immunometabolic complications in critically ill patients. European Journal of Clinical Investigation. 2024;54(9). doi:10.1111/eci.14229
BibTeX
@article{Galli2024,
author = {Galli, Francesco and Bartolini, Desirée and Ronco, Claudio},
title = {Oxidative stress, defective proteostasis and immunometabolic complications in critically ill patients},
journal = {European Journal of Clinical Investigation},
year = {2024},
volume = {54},
number = {9},
doi = {10.1111/eci.14229}
}
EUVIMED